An observational study in Amyotrophic Lateral Sclerosis, sponsored by Ambulanzpartner Soziotechnologie APST GmbH. Completed at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ambulanzpartner Soziotechnologie APST GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2015, is one of 13 observational ones, and was the 57th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:
Ambulanzpartner Soziotechnologie APST GmbH · Sites in Germany
Trace Neuroscience, Inc. · Sites in Germany, Netherlands, United Kingdom
Ages 18–75
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Leal Therapeutics, Inc · Sites in Germany, Italy, Netherlands and 1 more country
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 29 · Phase 3 25
First in 2003; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 219 across the 63 interventional studies, 200 across the 13 observational. Of the 48 that completed or were terminated, 23 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 76 have an industry lead sponsor. The 10 most frequent:
Ambulanzpartner Soziotechnologie APST GmbH is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ambulanzpartner Soziotechnologie APST GmbH has 3 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
| NCT06605612LMU KlinikumDevelopment and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | 2027-08-01 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with Amyotrophic lateral sclerosis (ALS), Spinal muscular atrophy (SMA) and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes.
This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with ALS, SMA and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes. The collected data include clinical characteristics, medical history, assessment scales, such as ALS functional rating scale-revised (ALSFRS-R), prognosis indicators, such as ALS progression rate, biomarker data, such as serum Neurofilament light chain (sNfL), genetic data, such as the mutation status of SOD1, FUS, c9orf72, TARDBP in ALS, SMN1 in SMA patients, innovative drugs such as Tofersen, Nusinersen, Risdiplam, as well as symptomatic drugs, patient-reported outcome data being captured using questionnaires and established clinical scales on medication expectation and treatment satisfaction.
The cohort includes patients with ALS, SMA and other chronic neurological conditions who received care with assistive devices, remedies, medications, or nursing interventions.
Inclusion Criteria: Diagnosis of a chronic neurological disease -
Exclusion Criteria: Lack of cooperation and unwillingness to store and share medical data collected in the registry study
-
The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires
The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires
Time frame: 10 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in Dec 2024, 110 months.
Of 138 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's 110 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2028 → Dec 2024 and completion Jun 2029 → Dec 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Ambulanzpartner Soziotechnologie APST GmbH